Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fasudil - Asahi Kasei/Woolsey Pharmaceuticals

Drug Profile

Fasudil - Asahi Kasei/Woolsey Pharmaceuticals

Alternative Names: AT 877; Chuanwei; Eril; Eril Injection S; HA 1077

Latest Information Update: 05 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asahi Kasei
  • Developer Asahi Kasei; Asahi Kasei Pharma Corp; Eisai Co Ltd; Tianjin Chase Sun Pharmaceutical
  • Class Amines; Anti-ischaemics; Ischaemic heart disorder therapies; Isoquinolines; Small molecules; Sulfonamides
  • Mechanism of Action Calcium channel antagonists; Protein kinase C inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cerebral ischaemia; Cerebral vasospasm
  • No development reported Pulmonary arterial hypertension
  • Discontinued Angina pectoris; Atherosclerosis; HIV-1 infections; Intracranial thrombosis

Most Recent Events

  • 25 Nov 2019 Fasudil licensed to Woolsey Pharmaceuticals worldwide, excluding China, Hong Kong, Japan, Macau, South Korea, Taiwan
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Pulmonary-arterial-hypertension in China (PO)
  • 27 Dec 2013 Discontinued - Preclinical for Cerebral ischaemia in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top